Navigation Links
Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
Date:9/22/2008

Common Genetic Variations Predict Patient Response to Novel Beta Blocker

Therapy

TORONTO, Sept. 22 /PRNewswire/ -- Bucindolol, an investigational, pharmacologically unique beta-blocker and mild vasodilator, significantly reduces hospitalization and death among heart failure patients with very favorable genotypes, according to results of a large DNA study presented today as a poster at the annual meeting of the Heart Failure Society of America. Researchers found that common genetic variations can predict which heart failure patients will have the greatest therapeutic response to bucindolol.

ARCA biopharma has submitted a New Drug Application (NDA) for bucindolol to the U.S. Food and Drug Administration for the treatment of chronic heart failure.

"The ability to predict patient response to bucindolol makes it easier for physicians to match the right patient to the right medicine, potentially avoiding months of trial-and-error therapy and helping very sick heart failure patients achieve better outcomes sooner," said Christopher O'Connor, M.D., Director of the Heart Center at Duke University Medical Center and presenter of the study. "This data brings us much closer to realizing the benefits of personalized medicine in heart failure."

The prospectively-designed DNA sub-study included more than 1,000 patients enrolled in the Beta-Blocker Evaluation of Survival Trial (BEST), the largest heart failure mortality trial conducted primarily in the United States. Researchers evaluated therapeutic response to bucindolol among patients with genetic variations, or polymorphisms, in two adrenergic receptors that help regulate cardiac function: beta 1 389 Arg/Gly and alpha 2c 322-325 WT/Del. Researchers identified three distinct genotypes that predict the effect of bucindolol: very favorable (47% of BEST patients), favorable (40%) and unfavorable (13%).

In the study, patients with the very favorable genotype
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
3. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
4. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, ... aesthetic products for skin and hair rejuvenation, has ... as agency of record for investor relations and ... improve our distribution, sales and diversification strategies – ... current and prospective shareholders," stated Ali Kharazmi CEO ...
(Date:2/26/2015)... 26, 2015 The Pittcon 2015 ... the Ernest N. Morial Convention Center in New ... of February 19, 2015) displaying products and services ... and government labs. The Exposition will offer the ... limited to, analytical chemistry; drug discovery; nanotechnology; life ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Pittcon 2015 Announces Exposition Highlights 2
... PALO ALTO, Calif., Oct. 24 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... third quarter 2007 financial results on Tuesday, November 6, ... Pharmaceuticals,will host an investor conference call and live audio ... November 6, 2007, at 5:00 p.m.,Eastern Time/2:00 p.m. Pacific ...
... Environment Where Scientists Thrive and Science is ... ... year, Abbott (NYSE: ABT ) has been named among the top ... Science is at the center of Abbott,s broad base of businesses. To,enhance ...
... Leading US Spine Centers Committed to the IEP,s ... 24 Magnifi Group, considered by,many industry observers ... within the medical device and pharmaceutical industries,announced here ... annual,meeting, its intent to organize and develop real-time ...
Cached Biology Technology:Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 3Magnifi Group Demonstrates Industry's First Interactive Educational Program (IEP) for Spine Fellows 2
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Institutes for Health (NIH) have awarded $4.5 million to ... artificial pancreas system that will monitor and adapt to ... This collaboration between physicians and engineers aims to merge ... human behavior, physiology, and medical technology and ultimately ...
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2011.   Revenue for the third quarter of ... million in the same quarter last year. Net income for the ... share. These results compared to net income of $76,000, or $0.00 ...
... The Greenland ice sheet can experience extreme melting even when ... by Dr. Marco Tedesco, assistant professor in the Department of ... York. His findings suggest that glaciers could undergo a ... to halt. "We are finding that even if you ...
Cached Biology News:NIH awards group $4.5 million for smart artificial pancreas technology 2NIH awards group $4.5 million for smart artificial pancreas technology 3Aware, Inc. Reports Third Quarter 2011 Financial Results 2Aware, Inc. Reports Third Quarter 2011 Financial Results 3Aware, Inc. Reports Third Quarter 2011 Financial Results 4Aware, Inc. Reports Third Quarter 2011 Financial Results 5Extreme melting on Greenland ice sheet, reports CCNY team 2Extreme melting on Greenland ice sheet, reports CCNY team 3
Request Info...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
...
Biology Products: